Release Date: 08/02/16 08:51 Summary: Supplementary Target's Statement Price Sensitive: Yes Download Document 620.56KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%